All In Biotech

Drug Trial Radar · NCT00763022

Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of TAK-559 Compared to Placebo in the Treatment of Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Nov 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 302 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

302

Actual

Start

Nov 2003

Primary completion

Dec 2004

Study completion Dec 2004

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 30, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.

Conditions

  • Diabetes Mellitus

Interventions

  • TAK-559Drug

    TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.

  • TAK-559Drug

    TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.

  • PlaceboDrug

    TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Baseline in Glycosylated hemoglobin.Time frame: Weeks: 4, 8, 12, 16, 20 and Final Visit.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.